ARCA biopharma, Inc. (Nasdaq: ABIO) is a privately held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases.  The Company’s first product is bucindolol, a third generation beta-blocker-vasodilator for advanced heart failure and other indications, that promises to be the first genetically-targeted cardiovascular drug.  Bucindolol has extensive Phase III data and a unique Phase III DNA sub study.  Using this sub study, ARCA’s founding scientists have confirmed two genetic polymorphisms that interact with bucindolol's unique pharmacology to modify patient response.  ARCA anticipates submitting an application with the FDA for approval of bucindolol in 2008.